Pharmaceutical company Medac Pharma Inc stated on Friday that the Patent Trial And Appeal Board (PTAB) has decided to uphold the patentability of all the claims of its '231 patent" for Rasuvo.
The company said the PTAB has upheld all 22 claims that belongs to its parent company medac GmbH's patent covering its rheumatoid arthritis treatment, Rasuvo, an auto-injector that provides highly concentrated doses of methotrexate.
Following the PTAB ruling, Medac now ends the patent challenge brought by Koios Pharmaceuticals LLC.
According to the company's CEO Terri Shoemaker, the patent, which is based on Medac's pioneering work to bring methotrexate treatment to patients in need of safe, less painful, and easy to use form, does not expire until 2029.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007